GSK Gets FDA OK on Treatment for Myelofibrosis Patients with Anemia
15 Setembro 2023 - 9:17PM
Dow Jones News
By Ben Glickman
GSK has received approval from the Food and Drug Administration
for its treatment for myelofibrosis.
The British pharmaceutical company said Friday that Ojjaara had
been approved for the treatment of intermediate or high-risk
myelofibrosis patients with anemia.
The company said myelofibrosis is a blood cancer affecting about
25,000 patients in the U.S.
GSK initially submitted Phase 3 trial data on the drug, which
has generic name momelotinib, in August 2022.
The treatment is approved for use regardless of whether patients
have received prior myelofibrosis therapy.
Momelotinib isn't currently approved in any other market.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 15, 2023 20:02 ET (00:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
